{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:34:33Z","timestamp":1789148073631,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.tmrv.2022.08.001","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T04:13:54Z","timestamp":1662437634000},"page":"175-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["New Therapies for the Treatment of Warm Autoimmune Hemolytic Anemia"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0857-8379","authenticated-orcid":false,"given":"Bruno","family":"Fattizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.tmrv.2022.08.001_bib0001","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/blood.2019003808","article-title":"How I treat warm autoimmune hemolytic anemia","volume":"137","author":"Barcellini","year":"2021","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.tmrv.2022.08.001_bib0002","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.tmrv.2022.08.001_bib0003","doi-asserted-by":"crossref","first-page":"E243","DOI":"10.1002\/ajh.25212","article-title":"Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers","volume":"93","author":"Barcellini","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.tmrv.2022.08.001_bib0004","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/ijlh.13469","article-title":"Features of serum complement C3 and C4 levels in autoimmune hemolytic anemia patients","volume":"43","author":"Wang","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.tmrv.2022.08.001_bib0005","series-title":"Immune Hemolytic Anemias","author":"Petz","year":"2004"},{"issue":"12","key":"10.1016\/j.tmrv.2022.08.001_bib0006","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.3390\/jcm9123859","article-title":"New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1","volume":"9","author":"Barcellini","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.tmrv.2022.08.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.tmrv.2022.08.001_bib0008","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.autrev.2014.11.014","article-title":"Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies","volume":"14","author":"Reynaud","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"16","key":"10.1016\/j.tmrv.2022.08.001_bib0009","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood-2011-06-363556","article-title":"Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies","volume":"119","author":"Barcellini","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2022.08.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221097780","article-title":"Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers","volume":"13","author":"Fattizzo","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"10.1016\/j.tmrv.2022.08.001_bib0011","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00277-018-3553-9","article-title":"Prognosis of autoimmune hemolytic anemia in critically ill patients","volume":"98","author":"Lafarge","year":"2019","journal-title":"Ann Hematol"},{"issue":"24","key":"10.1016\/j.tmrv.2022.08.001_bib0012","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1182\/bloodadvances.2021005610","article-title":"Evans syndrome in adults: an observational multicenter study","volume":"5","author":"Fattizzo","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.tmrv.2022.08.001_bib0013","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3389\/fimmu.2020.00946","article-title":"The Changing Landscape of Autoimmune Hemolytic Anemia","volume":"11","author":"Barcellini","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.tmrv.2022.08.001_bib0014","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/bjh.16009","article-title":"Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia","volume":"187","author":"Fadlallah","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.tmrv.2022.08.001_bib0015","doi-asserted-by":"crossref","first-page":"e28679","DOI":"10.1097\/MD.0000000000028679","article-title":"Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia","volume":"101","author":"Yao","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.tmrv.2022.08.001_bib0016","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.26508","article-title":"Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study","volume":"97","author":"Kuter","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.tmrv.2022.08.001_bib0017","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3324\/haematol.2020.250522","article-title":"Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study","volume":"106","author":"Fattizzo","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.tmrv.2022.08.001_bib0018","series-title":"Efficacy and safety results from an open-label phase 2 study of prsaclisib for the treatment of autoimmune hemolytic anemia","author":"Barcellini","year":"2022"},{"key":"10.1016\/j.tmrv.2022.08.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211046428","article-title":"Bortezomib in autoimmune hemolytic anemia and beyond","volume":"12","author":"Pasquale","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"10.1016\/j.tmrv.2022.08.001_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-based antibody depletion for refractory autoimmune hematological diseases","volume":"1","author":"Ratnasingam","year":"2016","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.tmrv.2022.08.001_bib0021","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1182\/blood-2018-03-835413","article-title":"Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.tmrv.2022.08.001_bib0022","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/1744666X.2018.1521722","article-title":"Current and emerging treatment options for autoimmune hemolytic anemia","volume":"14","author":"Barcellini","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"10.1016\/j.tmrv.2022.08.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191043","article-title":"SYK degradation restrains plasma cell formation and promotes zonal transitions in germinal centers","volume":"217","author":"Davidzohn","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.tmrv.2022.08.001_bib0024","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3389\/fimmu.2018.00787","article-title":"SYK inhibition induces apoptosis in germinal center-like B cells by modulating the antiapoptotic protein myeloid cell leukemia-1, affecting B-cell activation and antibody production","volume":"9","author":"Roders","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.tmrv.2022.08.001_bib0025","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"14","key":"10.1016\/j.tmrv.2022.08.001_bib0026","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2008-07-166439","article-title":"Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk","volume":"113","author":"Podolanczuk","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.tmrv.2022.08.001_bib0027","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/annrheumdis-2014-205361","article-title":"OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy","volume":"74","author":"Taylor","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"10.1016\/j.tmrv.2022.08.001_bib0028","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.tmrv.2022.08.001_bib0029","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.tmrv.2022.08.001_bib0030","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ajh.25444","article-title":"Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program","volume":"94","author":"Bussel","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2022.08.001_bib0031","unstructured":"Available at https:\/\/www.rigel.com\/investors\/news-events\/press-releases\/detail\/338\/rigel-announces-top-line-results-from-forward-phase-3. Last accessed on 28 June 2022."},{"issue":"3","key":"10.1016\/j.tmrv.2022.08.001_bib0032","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000339260","article-title":"Erythropoietin May Improve Anemia in Patients with Autoimmune Hemolytic Anemia Associated with Reticulocytopenia","volume":"39","author":"Arbach","year":"2012","journal-title":"Transfus Med Hemother"},{"issue":"6","key":"10.1016\/j.tmrv.2022.08.001_bib0033","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000366244","article-title":"The effect of erythropoiesis-stimulating agents in patients with therapy-refractory autoimmune hemolytic anemia","volume":"41","author":"Salama","year":"2014","journal-title":"Transfus Med Hemother"},{"issue":"12","key":"10.1016\/j.tmrv.2022.08.001_bib0034","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3324\/haematol.13255","article-title":"Anemia of chronic disease and defective erythropoietin production in patients with celiac disease","volume":"93","author":"Bergamaschi","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.tmrv.2022.08.001_bib0035","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.thromres.2014.10.012","article-title":"Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees","volume":"135","author":"Yusuf","year":"2015","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.tmrv.2022.08.001_bib0036","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/rth2.12333","article-title":"Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis","volume":"4","author":"Broome","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"10.1016\/j.tmrv.2022.08.001_bib0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207218","article-title":"Venous thromboembolic events during warm autoimmune hemolytic anemia","volume":"13","author":"Audia","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.tmrv.2022.08.001_bib0038","doi-asserted-by":"crossref","DOI":"10.1111\/jth.15757","article-title":"Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia","author":"Fattizzo","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tmrv.2022.08.001_bib0039","first-page":"1","article-title":"Autoimmune hemolytic anemia: causes and consequences","author":"Fattizzo","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.tmrv.2022.08.001_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.649441","article-title":"The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease","volume":"12","author":"Zaninoni","year":"2021","journal-title":"Front Immunol."},{"issue":"14","key":"10.1016\/j.tmrv.2022.08.001_bib0041","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in Cold Agglutinin Disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796322000396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796322000396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:20:19Z","timestamp":1760138419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796322000396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0887796322000396"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2022.08.001","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Therapies for the Treatment of Warm Autoimmune Hemolytic Anemia","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2022.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}